GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lee's Pharmaceutical Holdings Ltd (HKSE:00950) » Definitions » Ending Cash Position

Lee's Pharmaceutical Holdings (HKSE:00950) Ending Cash Position : HK$217 Mil (As of Dec. 2024)


View and export this data going back to 2002. Start your Free Trial

What is Lee's Pharmaceutical Holdings Ending Cash Position?

Lee's Pharmaceutical Holdings's Ending Cash Position for the quarter that ended in Dec. 2024 was HK$217 Mil.

Lee's Pharmaceutical Holdings's quarterly Ending Cash Position increased from Dec. 2023 (HK$168 Mil) to Jun. 2024 (HK$191 Mil) and increased from Jun. 2024 (HK$191 Mil) to Dec. 2024 (HK$217 Mil).

Lee's Pharmaceutical Holdings's annual Ending Cash Position declined from Dec. 2022 (HK$189 Mil) to Dec. 2023 (HK$168 Mil) but then increased from Dec. 2023 (HK$168 Mil) to Dec. 2024 (HK$217 Mil).

Lee's Pharmaceutical Holdings Ending Cash Position Historical Data

The historical data trend for Lee's Pharmaceutical Holdings's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lee's Pharmaceutical Holdings Ending Cash Position Chart

Lee's Pharmaceutical Holdings Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 375.20 277.53 189.30 167.53 216.85

Lee's Pharmaceutical Holdings Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -178.75 161.52 167.53 190.79 216.85

Lee's Pharmaceutical Holdings Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Lee's Pharmaceutical Holdings's Ending Cash Position for the fiscal year that ended in Dec. 2024 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=167.528+49.317
=217

Lee's Pharmaceutical Holdings's Ending Cash Position for the quarter that ended in Dec. 2024 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=190.794+26.051
=217

Lee's Pharmaceutical Holdings Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Lee's Pharmaceutical Holdings's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Lee's Pharmaceutical Holdings Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lee's Pharmaceutical Holdings Ltd (HKSE:00950) » Definitions » Ending Cash Position
Comparable Companies
HKSE:03737 HKSE:00239 HKSE:08049 HKSE:08329 HKSE:00897 HKSE:00455 HKSE:03839 HKSE:01011 HKSE:01498 HKSE:01652 ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XSWX:GALD NSE:DIVISLAB HKSE:03692 XSWX:SDZ XTAE:TEVA
Traded in Other Exchanges
N/A
Address
Hong Kong Science Park, 1st Floor, Building 20E, Phase 3, Shatin, Hong Kong, HKG
Website
https://www.leespharm.com
Lee's Pharmaceutical Holdings Ltd is a research-driven and market-oriented biopharmaceutical company. Along with its subsidiaries, it develops, manufactures, sells, and markets pharmaceutical products. It focuses on cardiovascular, women's health, pediatrics, rare diseases, oncology, dermatology, and obstetrics. The company's reportable segments are; Proprietary and generic products which generates key revenue, and Licensed-in products. The Proprietary Products portfolio includes Livaracine, Yallaferon, Slounase, and Nadroparin Calcium Injection. Its Licensed-in Products include Centraxal Plus, Dicoflor, Ferplex, and Natulan among others. Geographically, the company generates a majority of its revenue from the People's Republic of China.
Executives
Lion River I N.v. 2201 Interest of corporation controlled by you
Li Zhenfu 2201 Interest of corporation controlled by you
Assicurazioni Generali Spa 2201 Interest of corporation controlled by you
Leelalertsuphakun Wanee 2101 Beneficial owner
Huang Zuie-chin 2201 Interest of corporation controlled by you
Lue Shuk Ping Vicky 2202 Interest of your spouse
Li Xiaoyi 2101 Beneficial owner
Lee Siu Fong 2101 Beneficial owner
Ubs Group Ag 2201 Interest of corporation controlled by you
Panacea Venture Healthcare Fund Ii, L.p. 2101 Beneficial owner
Panacea Innovation Limited 2201 Interest of corporation controlled by you
Guang Dong Min Ying Tou Zi Gu Fen You Xian Gong Si 2201 Interest of corporation controlled by you
Apta Finance Sa 2201 Interest of corporation controlled by you
Qualister Sa 2101 Beneficial owner
Paponi Claudia 2202 Interest of your spouse

Lee's Pharmaceutical Holdings Headlines

No Headlines